Maximize Your Wallet: Best Cards To Use With Chase Sapphire Preferred
Batman and Robin, peanut butter and jelly—some things are just better in pairs, including the best credit card combinations. The Chase Sapphire Preferred® Card is one that, while powerful on its own, can give you next-level value when coupled with the right partner.
There's a long list of attributes that make the Sapphire Preferred such a stellar product and one of the best rewards cards on the market, so let's get into it:
For all the Sapphire Preferred's strengths, there's still room for improvement. For example:
This is where pairing the Sapphire Preferred with another credit card can take your points earning to the next level.
The Chase Freedom Unlimited® is a no annual fee card with simple yet versatile rewards earning: 5% cash back on travel purchased through Chase Travel℠, 3% cash back on eligible dining and drugstores and 1.5% on all other purchases.
It's a solid card on its own, but when paired with the Sapphire Preferred, it becomes a powerful tool for maximizing every dollar you spend. What makes this pairing so effective is how well the two cards complement each other.
The Sapphire Preferred shines in categories like travel and dining, while the Freedom Unlimited picks up everything else with a minimum above-average return of 1.5X. Instead of settling for the Sapphire Preferred's underwhelming 1X on nonbonus purchases, you can route that spending through the Freedom Unlimited and boost your base earnings by 50%.
Since both cards earn Chase Ultimate Rewards® points, combining them means you not only earn more, you also unlock better redemption value through the Sapphire Preferred's 25% travel portal boost or its valuable airline and hotel transfer partners.
The no annual fee Chase Freedom Flex® brings rotating 5% bonus categories to the table, making it a trusty sidekick for your Sapphire Preferred. While it earns just 1% back on most purchases, the real value lies in its quarterly bonus categories, where you can earn 5% back on things like gas, grocery stores and online shopping. You'll earn 5% cash back on up to $1,500 in combined purchases in categories that rotate quarterly (requires activation), 5% cash back on travel purchased through Chase Travel℠, 3% cash back on dining and drugstores and 1% cash back on all other purchases.
The Sapphire Preferred doesn't offer rotating categories, so the Flex fills a valuable gap, especially if your spending habits shift throughout the year. And like the Freedom Unlimited, it earns Chase Ultimate Rewards® points that become far more valuable once moved to the Sapphire Preferred. That means you can earn 5X points on select categories and redeem those points at a boosted 1.25 cents through Chase Travel—or transfer them to travel partners for even bigger wins.
On the surface, the Sapphire Preferred and Capital One Venture X Rewards Credit Card (rates & fees) may look like competitors, but together they cover nearly every rewards gap. While the Sapphire Preferred focuses on bonus categories and point transfers, the Venture X offers flat-rate simplicity with 2X miles on every purchase—plus premium travel perks like lounge access and annual credits.
Where the Sapphire Preferred lacks luxury travel features, the Venture X delivers: Partner Lounge Network access, Capital One Lounge access and a $300 annual travel credit for bookings through Capital One Travel. That travel credit, plus a 10,000-mile anniversary bonus, help make up for the $395 annual fee (rates & fees). Access to Capital One's transfer partners means you have even more options when it's time to book your dream trip.
If you don't mind managing two issuers, this duo gives you premium travel perks, solid base earnings on every purchase and access to two of the most valuable rewards ecosystems.
The Chase Sapphire Preferred® Card is an impressive standalone travel card, but it becomes far more powerful when paired with the right partner—or two. Whether you want to earn more on everyday spending, take advantage of rotating bonus categories or enjoy premium travel perks, combining it with cards like the Freedom Unlimited, Freedom Flex or Venture X can help you earn more, redeem better and get the most from every dollar.
Find the best Chase credit card for your needs.
As long as you pay your cards on time, avoid carrying a balance and practice good credit habits, having multiple credit cards will not negatively impact your credit score. It can even help your score over time.
You don't have to stop at two cards to maximize your rewards and benefits. Take the Chase Trifecta, for example, where you can combine some of Chase's best cards, like the Chase Sapphire Reserve® or Preferred, with the Chase Freedom Flex and Chase Freedom Unlimited. Having a premium Ultimate Rewards card paired with no-annual-fee cash-back cards can unlock better earnings and more valuable redemption options.
Chase doesn't publish the exact score needed to be eligible for the Sapphire Preferred, but as a premium credit card, you'll need at least a good credit score (at least 670 on the FICO scoring scale).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' 'Patients diagnosed with advanced or metastatic renal cell carcinoma often face a median survival in months after exhausting standard therapies,' said Samer A. Srour, MB ChB, MS, Associate Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and lead investigator of the TRAVERSE trial. 'These updated results from a larger cohort of patients with confirmed CD70 positive tumors provide compelling evidence that treatment with ALLO-316 can reduce tumor burden, control disease, and in some cases deliver durable responses. These findings underscore the clinical promise of an allogeneic CAR T to address the significant unmet needs in solid tumors and offer hope to patients who have exhausted other options.' In the Phase 1b expansion cohort, 22 patients whose tumors had progressed on multiple prior therapies were treated with lymphodepletion and 20 were treated with ALLO-316. All patients had tumors resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had ≥2+ prior TKI, and 41% had prior belzutifan. Sixteen of the ALLO-316 treated patients had a high CD70 Tumor Proportion Score (TPS >50%). The Phase 1b expansion cohort evaluated the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) following a standard FC lymphodepletion regimen (fludarabine (30 mg/m2/day) and cyclophosphamide (500 mg/m2/day) for 3 days). The median time from enrollment to the start of therapy was four days. A single dose of ALLO-316 stabilized or reversed disease progression in the majority of patients. In the 16 patients with CD70 TPS ≥50%, the trial demonstrated a Confirmed Overall Response Rate (ORR) of 31% with 44% achieving a minimum of 30% reduction in tumor burden. Of the five confirmed responders, four maintain ongoing responses, with one in sustained remission for over 12 months. The median duration of response (mDOR) has not yet been reached, indicating the potential for long-term disease control. CD70+ patients Phase 1b(N=20) ORR (confirmed CR or PR per RECIST v1.1), n/N (%) 5/20 (25) CD70 TPS ≥50%CD70 TPS <50% 5/16 (31)0/4 (0) RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; TPS, tumor proportion score The safety profile of ALLO-316 was manageable and consistent with lymphodepletion and an active CAR T product. The most frequent Grade ≥3 events were hematologic and there were no treatment-related Grade 5 events. The most common all-grade adverse events were cytokine release syndrome (CRS) (68%; with no grade ≥3), neutropenia (68%), decreased white blood cell count (68%), anemia (59%), and thrombocytopenia (55%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was 18% (with no grade ≥3) and no graft-versus-host disease (GvHD) occurred. Improved recognition of IEC-HS symptoms led to diagnosis in 36% of patients with 2 patients (9%) experiencing a short-term Grade 3 (one) or Grade 4 (one patient) event. Newly implemented diagnostic and management algorithms significantly mitigated IEC-HS, with no associated Grade 5 events. TEAEs ≥20% incidence in Phase 1b, n (%) Phase 1b (N=22a) All Grades Grade ≥3 Neutropenia 15 (68) 15 (68) White blood cell count decreased 15 (68) 15 (68) Anemia 13 (59) 9 (41) Thrombocytopenia 12 (55) 6 (27) Nausea 8 (36) 0 ALT increased 7 (32) 2 (9) Peripheral edema 7 (32) 0 Pyrexia 7 (32) 0 Arthralgia 6 (27) 0 AST increased 6 (27) 2 (9) Fatigue 5 (23) 0 Headache 5 (23) 0 AEs of Special Interest Any Grade Grade ≥3 CRS 15 (68) 0 Infection 10 (45) 8 (36) IEC-HS 8 (36) 2 (9)b ICANS 4 (18) 0 Graft-versus-host disease 0 0 IEC-HS includes the preferred terms immune effector cell-associated HLH-like syndrome and Hemophagocytic lymphohistiocytosis. a Includes 2 patients who received LD but did not receive ALLO-316 b One patient experienced G4 IEC-HS based on GI bleeding with subsequent improvement and 1 patient experienced G3 IEC-HS based on hypotension managed without pressors with subsequent improvement. About ALLO-316 (TRAVERSE)ALLO-316 is an AlloCAR T™ investigational product targeting CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC. In October 2024 the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation based on the potential of ALLO-316 to address the unmet need for patients with advanced or metastatic RCC. The FDA previously granted Fast Track Designation (FTD) to ALLO-316 in March 2023. In April 2024, the Company announced an award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as 'develop,' 'potential,' 'expect,' 'can,' 'enable,' 'showing,' 'generate,' 'may,' 'could,' 'designed to,' 'promise,' 'hope,' 'ongoing,' 'indicating,' 'mitigate,' 'evaluate,' 'pioneer,' 'goal' or 'will,' including alternative forms thereof, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of ALLO-316 to treat patients with advanced or metastatic RCC or to provide meaningful clinical benefit in patients with advanced RCC; the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors and to generate deep and durable remissions; the potential that ALLO-316 can reduce tumor burden, control disease, and deliver durable responses; the design and potential benefits of our Dagger technology; whether the Dagger® technology will become the next-generation allogeneic platform; ALLO-316 and the Dagger technology's ability to enable robust CAR T cell expansion and persistence and tumor infiltration; the potential of ALLO-316 to address the unmet need in solid tumors or offer hope to patients who have exhausted other options; the transformative potential of our AlloCAR T™ in solid tumors; the potential advantages of the RMAT and Fast Track designation; and our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trials; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; RMAT and Fast Track designations may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval and the designations can be revoked if the criteria for eligibility cease to be met; and challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation under the 'Risk Factors' heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc. Allogene's investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T™ program. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Upturn
3 hours ago
- Business Upturn
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Journals
9 hours ago
- Business Journals
Alaska Airlines Lounge+ memberships help busy travelers relax, refuel
As a business traveler on the road about a third of his time, Brian M. Westbrook has developed a fine-tuned preflight routine. His favorite stop on his checklist: The Alaska Lounge, his 'oasis of calm' at the airport. Westbrook is a longtime Alaska Lounge+ member who regularly enjoys the relaxing environment in Alaska Airlines' West Coast lounges, as well as access to 90 partner lounges around the world. His work as a storyteller, event emcee/producer and technologist includes advocating for the digital guest experience at Alaska Airlines and keeps him flying at the airline's highest level – MVP Gold 100K status. Westbrook's Alaska Lounge+ membership allows him to make the most of his time at the airport before a flight and during connections. 'I know when I arrive early, I can treat myself to an hour in the lounge,' he said. One of Westbrook's favorite stops is the new 11,000-square-foot Alaska Lounge that opened in San Francisco International Airport's Harvey Milk Terminal 1 (SFO) in July 2024. The inviting design includes TalkBox® booths for private calls, as well as zones offering quiet nooks for working, a stylish bar to enjoy a craft beer or specialty cocktail and comfortable 'Signature Loungers' with views featuring floor-to-ceiling windows. Charging outlets are available at nearly every seat. expand As a self-described #avgeek, Westbrook especially appreciates the views of the gates throughout the SFO lounge. 'I love that I can watch the planes from anywhere,' he said. 'It's a fun way to stay connected to the airport.' This year, the Alaska Lounge at Ted Stevens Anchorage International Airport also was updated with double the seating, Signature Loungers and a design that takes inspiration from local artists. And a larger Alaska Lounge at Portland International Airport will open in 2026 — part of the airline's commitment to expanding its premium experience across its growing global network. 'Providing an elevated travel experience across all of our Alaska Lounges is just one way to show we care for our guests and thank them for their loyalty,' said Todd Traynor-Corey, vice president of guest products and experience, Alaska Airlines. Here are a few of the reasons that, regardless of his destination, you'll find Westbrook landing in an Alaska Lounge along the way: Fresh foods and thoughtful beverage choices All Alaska Lounge locations feature an inspired selection of fresh foods, along with complimentary local beers and wines, specialty cocktails, non-alcoholic beverages, and barista-crafted coffee. (At SFO, the coffee is roasted by the city's Ritual Coffee Roasters — and Westbrook will take his iced, please.) The SFO lounge also offers sourdough bread and spreads, and candy jars full of San Francisco treats. Westbrook is a longtime fan of the 'pancake printer' found in every Alaska Lounge, but his pro tip is for the lunch and dinner crowd. 'My biggest joy is the soup,' he said, calling out chicken with wild rice and turkey sausage lasagna as his top choices. He regularly posts a #SoupReport on Instagram and X. 'I like knowing I can pick up a good, healthy bite that I've already paid for,' Westbrook said. Exciting network growth and oneworld Alliance access In addition to the Portland lounge expansion coming in 2026, Westbrook is looking forward to new Alaska Lounges coming to Honolulu's Daniel K. Inouye International Airport and San Diego International Airport, along with an international Alaska Lounge planned for Sea-Tac International Airport in Seattle in the next few years. In the meantime, he's also making the most of his Lounge+ membership, which allows him to visit partner lounges around the world. 'Throughout the oneworld network, I have access,' he said. The most caring service Far and away, it's the concierges and staff in the Alaska Lounges who are the biggest draw for Westbrook. 'These are Alaska Airlines employees who know the system, love to travel and talk about the cool places they've been,' he said. He regularly relies on Alaska employees for travel tips — most recently for a Northern Lights tour out of Fairbanks, Alaska. 'The single most important benefit is the people,' he said. 'They all really care about my full journey.' Become an Alaska Lounge or Lounge+ member: Lounge members can enjoy our Alaska Lounges in San Francisco, Los Angeles, Portland, Seattle, Anchorage and New York (JFK). Lounge+ membership includes access to 90 partner lounges around the world. Both membership levels allow members to bring two guests or family members into the lounge. Learn more.
